Celonic Group announces CEO transition

26 August 2026

Switzerland-based Celonic Group today announced that Dr Samanta Cimitan, chief executive (CEO), will be leaving the company toward the end of 2026 to pursue a senior leadership opportunity with one of the world's leading life sciences global organization.

Over more than four years with Celonic, including more than three years as CEO, Dr Cimitan has successfully led the company through a period of strategic transformation, strengthening Celonic’s position as a pure-play biologics CDMO, enhancing its operational and commercial capabilities, and establishing a strong platform for sustainable long-term growth.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK